Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-22-005203
Filing Date
2022-03-31
Accepted
2022-03-31 16:12:47
Documents
67
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ikt-20211231.htm   iXBRL 10-K 3087571
2 EX-21.1 ikt-ex21_1.htm EX-21.1 8569
3 EX-31.1 ikt-ex31_1.htm EX-31.1 17351
4 EX-31.2 ikt-ex31_2.htm EX-31.2 18143
5 EX-32.1 ikt-ex32_1.htm EX-32.1 11399
6 EX-32.2 ikt-ex32_2.htm EX-32.2 11399
7 GRAPHIC img33818263_0.jpg GRAPHIC 99448
8 GRAPHIC img33818263_1.jpg GRAPHIC 477109
9 GRAPHIC img33818263_2.jpg GRAPHIC 159931
  Complete submission text file 0000950170-22-005203.txt   10339611

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ikt-20211231_def.xml EX-101.DEF 171372
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20211231_lab.xml EX-101.LAB 413240
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20211231_pre.xml EX-101.PRE 306571
13 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ikt-20211231_cal.xml EX-101.CAL 35603
14 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20211231.xsd EX-101.SCH 47975
61 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20211231_htm.xml XML 1128487
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39676 | Film No.: 22792635
SIC: 2836 Biological Products, (No Diagnostic Substances)